ATCC and the Broad Institute reported engineered, isogenic cancer models that replicate resistance mechanisms to targeted therapies, starting with EGFR-mutant non-small cell lung cancer treated with osimertinib. The work builds a panel of drug-resistant models using CRISPR gene editing and gene overexpression to accelerate resistance studies. The researchers said the approach enables drug-sensitive and drug-resistant cell lines to be studied side by side to identify escape pathways and combination strategies. They positioned the tool release as a resource for the wider research community, aiming to shorten the time needed to generate clinically relevant resistance datasets. The effort is led by William R. Sellers at the Broad Institute and includes Fang Tian and Francisca Vazquez from ATCC and Broad’s DepMap program.